Table 1.

Baseline characteristics and treatments of patients with GCA

	(N=65)
Age, mean (SD)	70.8 (9.2)
Female sex	44 (67.7)
Biopsy-proven disease	40 (61.5)
Imaging-proven disease*	21 (32.3)
New-onset disease at TCZ initiation†	27 (41.5)
Initial TCZ treatment
4 mg/kg intravenously monthly	2 (3.1)
8 mg/kg intravenously monthly	13 (22.0)
162 mg subcutaneously every 2 weeks	6 (9.2)
162 mg subcutaneously weekly	44 (67.7)
Use of other immunosuppressants for GCA
Concurrent with TCZ	2 (3.1)‡
Previous to TCZ	8 (12.3)§
On prednisone at TCZ initiation	65 (100)
Daily prednisone dose (mg) at TCZ initiation, mean (SD)	33.9 (21.5)
Patients receiving >1 TCZ course	13 (20.0)
Duration of first TCZ course (years), mean (SD)	1.9 (1.1)
Total duration of TCZ treatment (years), mean (SD)	2.2 (1.6)¶

Values represent number and (%) unless otherwise specified.

*Ultrasound, CT angiography, MR angiography or positron emission tomography showing arterial lesions suggestive of vasculitis.

†TCZ started within 12 weeks of GCA diagnosis without preceding disease flare.

‡Methotrexate in both cases.

§Including methotrexate, cyclophosphamide, ustekinumab, abatacept, tofacitinib and secukinumab.

¶Aggregated time on TCZ for patients who received more than one TCZ course.

GCA, giant cell arteritis; TCZ, tocilizumab.